Evotec Streamlines Testing of Quarter Million Compounds with Promega HaloTag® Technology
MADISON, WISCONSIN (May 27, 2009)
Evotec recently completed its largest screening project with the use of Promega HaloTag® technology. Evotec reported screening over 250,000 unique compounds on live cells with an assay designed to detect the internalization of a novel membrane receptor. The results identified compounds that have potential to be first in class for the therapeutic area.
After extensive testing, Evotec reported that HaloTag delivered the strongest performance compared to other technologies. In contrast to other fluorescent proteins, the proteins fused with HaloTag do not fluoresce until the HaloTag binds a fluorescent ligand. HaloTag allowed Evotec scientists to specifically label receptors with low background levels and increased sensitivity compared to other technologies.
The screen was conducted with a throughput of over 10,000 compounds per day on a confocal plate imager, using a stably transfected cell line. After labeling the surface pool of receptors, compounds were screened for their ability to inhibit receptor internalization,
"We are pleased to be able to provide our customers with such rich information, so quickly," says Mark Slack, Senior Scientist at Evotec. "It is advanced technologies like HaloTag that continue to expand our capabilities and service to our pharmaceutical and biotech partners."
Cell surface receptors are frequently targeted for new drug compounds, and their localization in the cell often governs their cellular activity. Promega has specifically developed ligands for HaloTag of differing colors; some that do not enter the cell on their own along with ligands that do passively enter the cell. Using these tools, scientists can label different pools of HaloTag proteins- those inside and those on the cell surface.
About Promega
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 2,000
products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human
identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global
distributors. For more information about Promega, visit www.promega.com.
These pages contain communications on Promega product releases and corporate activities. For additional new product information, see the
new products page or the specific product or application area.
For more information about a new release article or about Promega in general, contact Penny Patterson at 1-608-274-4330 or complete this
form.